[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depression-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depression-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053310","accelerated-high-dose-tdcs-for-depression-100053310",false,"NCT07226011","Accelerated High-Dose tDCS for Depression","Accelerated High-Dose tDCS for Depression: An Open-Label Outpatient Pilot Study","Inclusion Criteria:\n\n* Ages 18-70.\n* Current MDD diagnosis (MINI v7).\n* Baseline PHQ-9 \\> 9.\n* Capacity to consent\n* Fluent English.\n\nExclusion Criteria:\n\n* Bipolar or psychotic disorder\n* Primary anxiety disorders without concomitant major depression as defined above\n* Current significant suicidal ideation or behaviors require a higher level of care.\n* Use of neuromodulation therapies (e.g., ECT, TMS, VNS) within the past 6 months.\n* History of seizures, implanted cranial\u002F cardiac metal, or neurosurgery.\n* Use of medications that significantly reduce seizure threshold\n* Frequent\u002Fsevere HA\n* Personal history of head trauma, concussion, or TBI\n* Catatonic or otherwise unable to perform the consent process\n* Current alcohol or substance-use disorder (moderate-severe).\n* Any non-uniformities in the skin under the electrode site, including eczema, severe rashes, hyperhidrosis, communicable skin disorders, sensitive skin (ex. eczema, severe rashes), blisters, open wounds, burns including sunburns, cuts or irritation (e.g. due to shaving), or other skin defects or lesions, as determined by clinical personnel\n* Pregnancy (urine test required for women of childbearing potential).","ALL","18 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp.\n\nThe study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.",[27,28],"Major Depression","Major Depression Disorders",[30,31,32,33,34,35],"Depression","Nervous System","tDCS","Interventional","Brain Stimulation","Transcranial Direct Stimulation","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2025-12-15",{"date":44,"type":21},"2026-10-01",{"name":46,"class":47},"Medical University of South Carolina","OTHER",1,{"id":50,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":25,"conditions":53,"keywords":54,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":48},"100610317",{"count":20,"type":21},[24],[27,28],[30,31,32,33,34,35],"2026-05-11",{"date":57,"type":40},"2026-05-12",{"date":42,"type":40},{"date":60,"type":21},"2026-08-01",{"name":46,"class":47},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":48},"100618288","an-examination-of-the-performance-of-qbmobile-in-differential-diagnosis-associated-with-adhd-symptoms-100618288","NCT07329673","An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms","An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms.","Inclusion Criteria:\n\n* Provide written informed consent (including parent\u002Flegal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;\n* Aged \\> 6 years and \\\u003C 60 years old;\n* Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment;\n* Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures;\n* Have adequate sensory and physical ability to complete QbMobile;\n* Possess or have access to an iPhone model that supports QbMobile.\n\nExclusion Criteria:\n\n* Intellectual disability designated by IQ\\\u003C70;\n* Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder;\n* Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity\u002Fimpulsive presentation);\n* Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc);\n* Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);\n* Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance;\n* Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.","6 Years","60 Years",{"count":72,"type":21},300,"OBSERVATIONAL","The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.",[76,77,28,78,79,80],"Bi-Polar Disorder","Autism Spectrum Disorder (ASD)","Separation Anxiety Disorder","Social Anxiety Disorder","Generalized Anxiety Disorder (GAD)","2026-05-04",{"date":83,"type":40},"2026-05-06",{"date":85,"type":40},"2026-01-01",{"date":87,"type":21},"2026-11",{"name":89,"class":90},"Qbtech AB","INDUSTRY"]